The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characterization of the mTOR autophosphorylation site, S2481, as a novel biomarker in renal cell carcinoma (RCC).
Lauren Christine Harshman
Consultant or Advisory Role - Theragene (U)
Karra Muller
No relevant relationships to disclose
Chii-Dean Lin
No relevant relationships to disclose
James D. Brooks
No relevant relationships to disclose
John Higgins
No relevant relationships to disclose
Jon Berglin
Employment or Leadership Position - Theragene
Stock Ownership - Theragene
Research Funding - Theragene
Tony Hunter
Consultant or Advisory Role - Theragene
Stock Ownership - Theragene
Jeremy Copp
Employment or Leadership Position - Theragene
Stock Ownership - Theragene